Nature Communications study addresses MDR typhoid

New study in Nature Communications reveals high burden of multi-drug resistant (MDR) typhoid fever in sub-Saharan Africa associated with two predominant genotypes – IVI epidemiologist Se […]

Typhoid conjugate vaccine from Indonesia found to be safe, immunogenic in phase 1 clinical trial

    SEOUL, Korea, JAKARTA, Indonesia, February 22, 2019 — Scientists from Bio Farma, the University of Indonesia, and the International Vaccine Institute (IVI), recently published […]

IVI receives $3.2 million grant to support TCV effectiveness studies in West Africa

  SEOUL, Korea — The International Vaccine Institute (IVI) has been awarded a $3,238,974 grant from the Bill & Melinda Gates Foundation to provide technical assistance […]

EuBiologics receives funding from the RIGHT Fund for the development of a cholera conjugate vaccine

      July 25, 2019 – SEOUL, South Korea. The International Vaccine Institute (IVI) is pleased to announce that EuBiologics, IVI’s key partner in Korea, […]